rawfin.tv
Biogen Completes RayThera Acquisition, Expands Immunology Pipeline
MarketsstocksAI Generated

Biogen Completes RayThera Acquisition, Expands Immunology Pipeline

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

Biogen has finalized its acquisition of RayThera Inc., a biotech company specializing in small-molecule therapies for immunology. This strategic move aims to bolster Biogen's drug development pipeline with RayThera's lead Phase 1 program.

BiogenAcquisitionBiotechnologyHealthcareImmunology

Related Articles

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

stocks
EQT to Acquire Cleanaway Waste for $6.5 Billion

EQT to Acquire Cleanaway Waste for $6.5 Billion

stocks
S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

stocks
US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

stocks